A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. T2 Biosystems Inc’s current trading price is -95.83% away from its 52-week high, while its distance from the 52-week low is -6.45%. The stock’s
The market performance of T2 Biosystems Inc has been somewhat unstable. Over the past year, the company’s stock achieved a high of $6.95 on 02/15/24, with the lowest value for the same timeframe being $0.31, recorded on 12/17/24. 52-week price history of TTOO Stock A
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -4.76%.However, over the last six months, we can see a
Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. T2 Biosystems Inc’s current trading price is -95.11% away from its 52-week high, while its distance from the 52-week low is 32.26%.
T2 Biosystems Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $8.38 on 12/28/23, while the lowest price for the same period was registered at $0.42 on 12/13/24. 52-week price history of TTOO Stock Studying a
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The metric has seen a significant loss of -92.43% since the start of this calendar
Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. T2 Biosystems Inc’s current trading price is -93.17% away from its 52-week high, while its distance from the 52-week low is 37.70%.
T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic-resistance genes, has recently submitted an application to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its Candida auris test. This move comes as the company
All rights reserved © 2024, Powered By Smart TechOne
